| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | S10; HSAS; MASA; MIC5; SPG1; CAML1; CD171; HSAS1; N-CAML1; NCAM-L1; N-CAM-L1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human L1CAM |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于L1CAM抗体的3篇参考文献及其摘要概括：
1. **文献名称**: *L1CAM antibodies block glioblastoma cell dissemination in vitro*
**作者**: Kiefel H, et al.
**摘要**: 该研究探讨了L1CAM抗体在抑制胶质母细胞瘤细胞迁移和侵袭中的作用，发现抗体通过阻断L1CAM介导的细胞黏附和信号通路，显著减少肿瘤细胞的扩散。
2. **文献名称**: *Anti-L1CAM monoclonal antibody targets neuroblastoma cells*
**作者**: Sorensen MD, et al.
**摘要**: 研究验证了一种新型抗L1CAM单克隆抗体在神经母细胞瘤中的治疗潜力，显示其可通过抗体依赖性细胞毒性(ADCC)特异性杀伤高表达L1CAM的肿瘤细胞。
3. **文献名称**: *L1CAM as a biomarker in ovarian cancer: Validation via immunohistochemistry*
**作者**: Fogel M, et al.
**摘要**: 该文献利用L1CAM抗体进行免疫组化分析，证实L1CAM在卵巢癌组织中的高表达与患者预后不良相关，提示其作为临床诊断和治疗的潜在靶点。
以上研究均聚焦于L1CAM抗体的应用，涵盖肿瘤治疗、机制探索及生物标志物开发方向。如需更多文献或特定领域研究，可进一步补充说明。
L1CAM (L1 cell adhesion molecule) is a transmembrane glycoprotein belonging to the immunoglobulin (Ig) superfamily. Initially identified for its role in nervous system development, L1CAM mediates cell-cell adhesion, neuronal migration, axon guidance, and synaptic plasticity through interactions with extracellular matrix components and cell-surface receptors like integrins. Structurally, it comprises six Ig-like domains, five fibronectin type III repeats, a transmembrane region, and a cytoplasmic tail involved in intracellular signaling.
L1CAM antibodies are essential tools in research and diagnostics. In neuroscience, they help study neural development and disorders such as CRASH syndrome (a rare X-linked condition caused by L1CAM mutations). Beyond the nervous system, L1CAM is implicated in cancer progression, where its overexpression correlates with tumor invasion, metastasis, and poor prognosis in cancers like endometrial carcinoma, glioblastoma, and melanoma. Antibodies targeting L1CAM are used in immunohistochemistry, flow cytometry, and Western blotting to detect expression patterns and assess its role in disease mechanisms.
Therapeutically, L1CAM antibodies are explored for targeted cancer treatments, including antibody-drug conjugates or immune checkpoint inhibitors. However, challenges remain in ensuring specificity and minimizing off-target effects. Recent studies also investigate L1CAM's role in autoimmune diseases and tissue regeneration, broadening its clinical relevance. Overall, L1CAM antibodies bridge fundamental research and translational applications, highlighting their importance in understanding cellular adhesion pathways and developing precision therapies.
×
